Dr. Kamalasanan is a Professor in the Department of Pharmaceutics, Amrita School of Pharmacy. He is the lead author of Roadmap for Biomaterials in Vision 2035 document by TIFAC, DST, India. He is an Industrial Pharmacist from Annamalai University and got trained in Biomaterials and Biomedical Engineering under Dr. Chandra P. Sharma at SCTIMST. He got trained in immunology under Prof. Harald Renz at Philipps University in Marburg, Germany. Later, he did three-year postdoctoral research with Dr. Steven R Little in interdisciplinary areas of immunotherapeutics, nanotechnology, and drug delivery at McGowan Institute for Regenerative Medicine and the Department of Chemical Engineering, Bioengineering, and Immunology, University of Pittsburgh, USA. After returning to India, he served as Chitra High Value Fellow Scientist-D at SCTIMST, India, for three years before moving to Amrita School of Pharmacy at Kochi, and is currently consulting for various organizations nationally and internationally. Dr. Kamalasanan has developed products that reached market filed several national and international patents, received numerous awards, and has several research articles, book chapters, and conference proceedings. He also actively participated in various professional society activities and has nearly 2 decades of research, technology development, and academic experience in translational medicine.

Dr. Chandra P. Sharma is Adjunct Professor, Department of Pharmaceutical Biotechnology, Manipal College of Pharmaceutical Sciences, Manipal University, and Hon. Emeritus Professor, College of Biomedical Engineering & Applied Sciences, Purbanchal University, Kathmandu, Nepal. Dr. Sharma is a Solid-State Physicist from IIT Delhi and received his training in Biomaterials area in the University of Utah with Prof. D.J. Lyman as a graduate student and in the University of Liverpool, England with Prof. D.F. Williams as a Post-Doctoral Research Associate. Dr. Sharma has been awarded FBSE (Fellow Biomaterials Science & Engineering) by The International Union of Societies for Biomaterials Science & Engineering (IUS-BSE) in 2008 and FBAO (Fellow Biomaterials and Artificial Organs) by Society for Biomaterials & Artificial Organs (India) (SBAOI) in 2011 and shares Whitaker and National Science Foundation Award International Society for Artificial Organs (ISAO) USA, invited member ACS (2015-2018).

Klappentext
Nanomedicine in Translational Research: Status and Future Challenges harnesses the current developments and future directions of diagnostic and therapeutic solutions in clinical scenarios. This book integrates nanomedicine and biomaterials to develop healthcare technology for improved patient care and clinical practices, through applications using theranostics, biomaterials, 3-D printing, regenerative medicines, and nanosystems. Those in this multidisciplinary field will need to improve procedures and protocols, as well as regulatory guidelines and their clinical implications. This book will be highly useful as it is written by experts in the field for researchers working in the areas of nanotechnology, biomaterials, drug delivery, and pharmaceuticals for chronic diseases.

Inhalt

Introduction
Properties of biomaterials at nano range
In vitro systems to demonstrate the nano effect
Toxicology of biomaterials at nanoscale
Porphyrinoid-based single molecule to nano theranostics towards personalized diagnosis and treatment
Nanomaterials for biomedical applications
Nanosystems - combination products
Biomass derived carbon nanodots
Nanosystems for Pharmaceutical applications
Scope of Biomaterials for theranostics application
Redox Nanotherapeutics: Fundamentals and Applications
Smart Therapeutics: Evolution from small biomolecules to synthetic cells
Applications of Artificial Intelligence and Machine Learning Models in Nanotherapeutics.
Nanomedicine in Patient-specific Clinical Trend: Shape memory polymers of emerging biomedical applications and their future prospects
Commercialized nanomedicines until to date
Nanosystems development, Quality Control requirements and ethical issues
Affordable and accessible nanomedicines: Regulatory perspectives from right to health